Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexicon Pharmaceuticals, Inc. on November 19, 2024. The filing reports corporate governance changes effective December 2, 2024, specifically the retirement of a director and the election of a new director.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Director Departure: Robert J. Lefkowitz, M.D., notified the company of his retirement from the Board of Directors, effective December 2, 2024. The filing states this was not due to any disagreement with the company.
- Director Election: Ivan H. Cheung was elected to the Board of Directors, effective December 2, 2024. He will initially serve on the Audit Committee.
Compensation and Governance Details
Mr. Cheung's compensation package includes standard cash retainers and an initial equity grant:
- Cash Retainers: $50,000 annual board retainer; $10,000 annual audit committee retainer. Additional retainers apply for service on other committees or as committee chair.
- Equity Grant: An initial stock option to purchase 186,685 shares of common stock. The exercise price equals the fair market value on the grant date.
- Vesting Schedule: The option vests in three equal tranches (one-third) on each of the first three anniversaries of the grant date.
- Indemnification: A standard indemnification agreement will be executed with Mr. Cheung.
Key Facts for Investor Verification
- Verify the effective date of the board composition change (December 2, 2024).
- Confirm the total number of shares subject to the new stock option grant (186,685) and its impact on dilution.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for these changes.
- Note that this filing contains no financial performance data; refer to recent 10-Q or 10-K filings for financial metrics.